Dr Rutherford asks: In the early 1970s, you, and your late wife Janice, studied adrenergic mechanisms and cardiac hypertrophy and ventricular function, as well, in spontaneously hypertensive rats. What led to your initial animal studies on acute myocardial infarction and your interest in the renin-angiotensin-aldosterone system? Dr Pfeffer replies: As graduate students in the Department of Physiology and Biophysics at the University of Oklahoma, my late wife, Janice, and I had the privilege to work under the tutelage of Edward D. Frohlich, MD, who is a pioneer in the hemodynamics of hypertension with a major emphasis on the response of the heart to the augmented workload imposed by hypertension. He was keenly interested in the functional consequences of developing left ventricular hypertrophy and obtained breeding stock of the newly developed Japanese strain of the SHR. We developed methods to assess hemodynamics and left ventricular function to compare normotensive with hypertensive rats during aging. We found a marked age-associated deterioration in contractile performance in the hypertensive rats that could be prevented by a variety of antihypertensive agents.
group including Drs Joanne Ingwall, Israel Mirsky, Oscar Bing, Michael Fishbein, and William Grossman. The grant focused on adaptive and maladaptive changes in energetics, contractile performance, and ventricular wall stress with left ventricular hypertrophy. This collaborative work was productive and enjoyable; however, our investigative attention shifted to an experimental model of MI.
Braunwald introduced the concept of limitation of myocardial infarct size in the 1970s and had led a number of investigative teams to vigorously pursue approaches to salvaging myocytes in multiple experimental models of MI. The academic excitement regarding the ability to limit necrosis (and infarct size) during the hyperacute phase of a myocardial infarct was palpable. Building on our expertise in hemodynamic characterization and left ventricular function in the rat, we initially quantitated the functional consequences of myocyte loss. Although the variability of infarct size in the rat coronary artery ligation model was less than ideal for assessing therapies to modify this process, the resulting wide range of infarct sizes provided a superb opportunity to relate the magnitude of the infarct to ventricular function and size.
As we had learned from our studies of hypertension, key insights came from longitudinal studies regarding left ventricular function and structure. It became apparent that there is a progressive process of ventricular dilatation, which we termed left ventricular remodeling, that is related to both the extent of the initial myocardial necrosis and the passage of time. Because we were comparing ventricular volumes at common distending pressures, we knew that this enlargement was not just distention and that it involved both infarcted and viable portions of the ventricle. We considered that these late structural changes (occurring after histological infarct healing) were in some ways analogous to our observations in the aging SHR. A new ACE inhibitor, captopril, had been shown to be particularly effective in attenuating the age-associated adverse structural and functional changes in the SHR. Therefore, we were well positioned to determine whether this therapy would also have a favorable influence on ventricular function and structure in the rat MI model.
In 1985, you and Janice published 2 pivotal articles on the influence of chronic captopril therapy after myocardial infarction in rodents on cardiac function, ventricular dilation, and 1-year survival. Can you discuss the design of these studies and the outcomes?
The studies of captopril therapy after MI were a direct extension of our prior work in the SHR where the ACE inhibitor, captopril, was very effective in preventing long-term consequences of the abnormal workload. Indeed, we (Janice, myself, Israel Mirsky, and Eugene Braunwald) demonstrated that captopril was not only effective in sustaining pump function and preserving the ejection fraction afterload relationship, but chronic therapy also attenuated the left ventricular chamber enlargement that occurred in the aging SHR. Peter Fletcher was instrumental in developing the technique to assess the passive pressure volume relationship of the left ventricle. By providing a quantitative comparison of ventricular volume at comparable filling pressures, his work permitted us to compare heart size across groups. In rats with histologically healed MI, the extent of left ventricular enlargement was directly related to infarct size.
Janice led a detailed study demonstrating the favorable impact of chronic captopril in rats with experimental MI. 1 In this rather extensive study, she showed that captopril improved pump function and, importantly, attenuated the progressive increase in ventricular volume. Her conclusion, "Thus, captopril attenuated the left ventricular remodeling (dilatation) and deterioration in performance that were observed in rats with chronic myocardial infarction," became the foundation for our transition to clinical studies.
There was another aspect of the animal studies that bolstered our rationale to test this concept in patients with MI. In contrast to the detailed hemodynamics, cardiac structure, and function studies that Janice led, I was given the primary responsibility to ascertain the impact of captopril on survival in the MI model. Because time of death was the major outcome variable, Janice was comfortable in my ability (at that time a fully trained cardiologist) to make this fundamental assessment! The most important determinant of survival was indeed the extent of the histological damage or infarct size. Our study did demonstrate that, in the experimental MI model, chronic treatment with captopril did prolong survival. The most marked improvement in survival was noted in the rats with a moderate-sized infarct treated with captopril 2 ( Figure 1 ). I fondly recall presenting these data at the European Society of Cardiology meeting where Professor Peter Sleight, the leader of the International Study of Infarct Survival Collaborative Group, went to the microphone and congratulated us on conducting "a proper clinical trial in rats."
Having made this observation in rodents, you embarked on a clinical study in humans within a month after a first myocardial infarction with left ventricular ejection fractions ≤45% and treated with either placebo or captopril for 1 year. Could you discuss FRAME OF REFERENCE Although we proved that captopril was beneficial for rats with experimentally induced MI, we understood the extrapolation to humans was far too uncertain. This huge gap between our animal findings and clinical medicine was well expressed by Dr Gervasio (Tony) Lamas, my major collaborator, in his insightful comment, "I am impressed with your animal studies and would like to work with you but I don't do rats." It was clear that the potential positive clinical implications of our animal findings were too important to leave untested. Serial echocardiographic studies in patients with acute MI from the group at Johns Hopkins had shown increases in left ventricular size related both to changes in the infarct, and the viable regions of myocardium, as well. These findings solidified the potential importance of finding a therapy to attenuate these adverse structural changes.
We next conducted a focused mechanistic placebocontrolled, double-blind randomized-controlled clinical trial to determine "whether, as in the animal model, long-term treatment with an ACE inhibitor alters the process of progressive ventricular chamber enlargement in patients." Since both our animal work and these clinical studies indicated that ventricular enlargement was more likely observed in those with more extensive MIs, we chose a patient population in the early convalescent phase of a first anterior Q-wave MI with a left ventricular ejection fraction of ≤45%.
This, my first prospective clinical trial, was made possible by the immense support from my coinvestigators: Gervasio (Tony) Lamas, Douglas Vaughan, Alfred Parisi, and Eugene Braunwald. Less obvious was the underlying support and encouragement from our colleagues, and the nurses and staff in the catheterization laboratories, as well, at the West Roxbury VA and Brigham and Women's Hospitals. In addition to a year of blinded (either placebo or captopril) therapy, our 59 patients consented to quantitative biplane left ventriculography, each performed by Tony and Doug, to assess the primary study end point of change in ventricular volume. Our data supported the conclusion, "This preliminary study indicates that after anterior infarction, ventricular enlargement is progressive and that captopril may attenuate this process…" The conceptual alignment of this proof-of-concept human data with the rat studies was greatly buoyed by the findings led by Harvey White, in New Zealand, showing the adverse impact on survival of even minor increases in left ventricular volume following myocardial infarction. Indeed, the acronym SAVE, Survival And Ventricular Enlargement (coined by Janice), highlighted the presumed mechanistic process we were addressing.
A strong rationale was not sufficient to launch a major morbidity and mortality randomized-controlled clinical trial. Our sponsor, E.R. Squibb, now Bristol-Meyers Squibb, was initially split between those concerned with One-year survival in placebo-treated rats decreased markedly in direct relationship to the increasing size of myocardial infarction. Long-term captopril therapy prolonged the survival of rats with infarcts (all infarcts). The most marked improvement was in rats with moderately sized infarcts (moderate infarcts). In this latter group, the 1-year survival was 21% on H 2 the negative market impact if captopril was not well tolerated or precipitated ischemia during an acute MI and others who shared our vision of its potential to improve long-term clinical outcomes. The late John Alexander signed a 2-page letter of agreement, and we embarked on our international journey (United States and Canada), with 45 sites linking 112 participating hospitals. With frequent investigator meetings discussing the evolving data concerning optimal MI care, and the logistics of our ongoing randomized-controlled clinical trial, as well, a special camaraderie was fostered during the years of SAVE.
A concern that impacted the design of SAVE was that the time course of the trial would not be sufficient to demonstrate proposed long-term benefits of this new use of an ACE inhibitor. Accordingly, we constructed the primary end point as a composite of death or major deterioration of left ventricular ejection fraction ≥9 U. This large fall in left ventricular ejection fraction was, in effect, our surrogate for overt adverse left ventricular remodeling, or identifying those patients with a much higher likelihood of death with longer follow-up. As it turned out, the composite end point was reduced (P=0.006) in the captopril-assigned group, as was the risk of death (P=0.019). Every prespecified definition of developing heart failure was also reduced in the captopril group. 4 We concluded that "In patients with asymptomatic left ventricular dysfunction after myocardial infarction, long-term administration of captopril was associated with an improvement in survival and reduce mortality and morbidity due to major cardiovascular events" (Figure 2) .
One of the SAVE substudies linked the shape of the left ventricle to adverse cardiovascular events after myocardial infarction. Could you discuss what was learned?
Ancillary questions were incorporated within SAVE. Our echocardiographic substudy, led by Dr Martin St. John Sutton, directly addressed the study rationale. 5 Beyond confirming that captopril attenuated ventricular enlargement following MI, by coupling with clinical events, they added the important missing observation that those patients who experienced enlargement were more likely to have an adverse cardiovascular event. Indeed, ventricular remodeling has since become a widely used surrogate in drug development. We also addressed our prestudy concerns about captopril inducing ischemic events, and showed that patients treated with captopril were less likely to have a recurrent MI or need cardiac revascularization during follow-up. Similar findings from the SOLVD Program provided the impetus for innovative basic investigative studies of the favorable impact of ACE inhibitors on atherosclerosis and also the rationale for important studies like HOPE, EUROPA, and PEACE extending the use of ACE inhibitors to those patients with vascular disease without left ventricular dysfunction. Jean Rouleau, MD, our Canadian leader, gleefully showed that the marked increase in coronary revascularization procedures in the United States in comparison with Canada was not associated with a difference in either cardiovascular morbidity or mortality.
Your research has continued in the areas of heart failure with, and without, preserved ejection fraction, hypertension, and kidney disease. What are your reflections about your work in recent years?
The successful completion of SAVE, along with the lessons and networks established, paved the way for me to continue to have important leadership opportunities in clinical trials. I have been privileged to be involved in impactful trials in nephrology, diabetes mellitus, coronary artery disease, and heart failure. However, 2 trials (1 past, 1 ongoing) are in direct line with SAVE. The development of angiotensin receptor blockers created the strong impression that this newer class would provide more complete inhibition and improved outcomes. In VALIANT, in close collaboration with Dr Robert Califf and the Duke team, we compared valsartan with captopril on the rates of death post-MI. Although not superior, the clinical benefits of the ACE inhibitor were, however, preserved by this angiotensin receptor blocker. Another special opportunity has occurred 3 decades since SAVE. We are trying to lower cardiovascular morbidity and mortality in patients with MI more than with an ACE inhibitor. PARADISE MI is currently comparing the combination of the neutral endopeptidase and angiotensin receptor blocker (sacubitril/valsartan) with ramipril. Most extraordinarily, in this major international trial attempting to outperform SAVE, I will once again be side by side with my mentor and friend Eugene Braunwald.
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